The latest: Online insurer Waterdrop Inc. (WDH.US) on Tuesday reported a third-quarter net profit of 170 million yuan ($24.4 million), reversing a 479 yuan million yuan loss in the same period last year and representing its third consecutive quarterly profit.

Looking up: The company’s third-quarter revenue fell 0.9% year-on-year to 772 million yuan. But operating costs and expenses dropped 50.5% to 640 million yuan, as the company implemented a strategy of “earn more and spend less.”

Take Note: The company’s “Waterdrop medical crowdfunding platform” recorded 59 million yuan in service fee revenue, which was insufficient to cover its 63.7 million yuan in direct costs.

Digging Deeper: Waterdrop Inc. was founded by Meituan (3690.HK) co-founder Shen Peng in 2016 and listed in New York in May last year. Its business includes the “Waterdrop insurance marketplace” and “Waterdrop medical crowdfunding platform.” The company started to take cost control measures at the end of last year in its drive to become profitable, and reached that goal this year. In this year’s third quarter, for example, it sharply lowered its sales and marketing expenses by 82.4% to 138 million yuan, reducing operating costs by more than half.

Market Reaction: Waterdrop’s U.S.-listed shares surged 13.7% to $2.08 on Tuesday after the announcement, closing at a new 52-week high.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

So-Young dolls up with move to high-end cosmetic surgery

So-Young dolls up with pivot to high-end services

The cosmetic services social media platform is developing its own clinics as well as a premium platform for high-end users Key Takeaways: So-Young reported an annual profit last year, reversing…

NEWS WRAP: Nayuki pours up first annual profit

The premium tea chain aims to expand through franchising to boost its growth amid intense competition  By Teri Yu  Premium tea seller Nayuki Holdings Ltd. (2150.HK) on Wednesday reported its first annual profit since…
Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs.

Akeso marks profit milestone with swift rights issue

Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs Key Takeaways: Akeso swung to an…